Projects funded by the European Regional Development Funds (ERDF)

- Ferrer has been granted with a financial aid for its Research and Development Project named FAB117-HC “New Allogeneic Cellular medicinal product for the Treatment of Patients with Acute Traumatic Spinal Cord Injury. Regulatory Study Phase I / II”. The Centre for the Development of Industrial Technology (CDTI) manages this financial aid that is co-funded by the European Regional Development Funds. FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells, and the main objective of the project is to evaluate the safety and tolerability of a single administration of FAB117-HC (ClinicalTrials.gov.Identifier:NCT02917291). The partially refundable grant approved amounts to € 688,857.

- ADVANCE (CAT) is a consortium led by the University of Barcelona and Ferrer, made up of by eighteen reference health organizations. As such, it integrates the main biomedical research and teaching centers in Catalonia, as well as public bodies, private foundations and Catalan healthcare companies.

The aim of the ADVANCECAT project is to create an organizational structure to accelerate the development of new advanced therapy medicines, for better management of resources in order to obtain the maximum benefit in the Catalan health system. The creation of a new collaborative network avoids possible overlaps between the various participating institutions and allows them to work in a coordinated way. The main areas of focus are cell therapy, gene therapy and tissue engineering.

The key success of the project has been the integration of organizations in the field of biomedical research, its clinical application and its industrial production. Together, strengths and opportunities have been identified to meet the challenges presented in the field of advanced therapies, enhance research and accelerate the development of new products with a qualitative impact on health systems. These serve as a basis for promoting new economic opportunities in Catalonia. Among the most important results of the whole project are the 8 Phase I and II clinical trials of advanced therapies that have been or are being carried out, in which 171 patients have been treated. In addition, 32 articles have been published in international journals and 3 are pending approval.

Organizations that form part of the ADVANCECAT project:

University of Barcelona (leader), Ferrer (co-leader), Banc de Sang i Teixits, Barcelona Macula Foundation, Bioibérica SA, Butler Scientifics SL, Centre de Medicina Regenerativa de Barcelona, Fundació Bosch i Gimpera, FC Barcelona Universitas - Muscletech Network, Fundació Hospital Universitari Vall d’Hebron
The project is integrated into the NEXTHEALTH community, and has been co-financed by the European Union within the framework of the European Regional Development Fund (ERDF) Catalonia 2014-2020 operational program.

- Ferrer Internacional S.A. has received a grant of €129,409,99 from the EU ERDF thanks to the energy efficiency aid program in the industrial sector for big companies and SMEs defined in the RD 263/2019 for the remodelling of the cooling water distribution system of the pharmaceutical production plant of Sant Cugat del Vallès (Barcelona) by changing pumps, incorporating variable frequency drives, a new hydraulic circuit and a new electrical and control system. The eligible investment has been €609,537,17 and the estimated energy saving is 42.78 toe / year.

- Ferrer Internacional has received a grant from the ERDF funds of the European Union amounting to €70,682 for the implementation of LED lighting in the pharmaceutical production plant of Sant Cugat del Vallès (Barcelona). The eligible investment is €308,481 and the energy saving generated is 68.75 toe / year.